David G Huntsman

List of Publications by Year
in descending order

253 papers	31,055 citations	4388 86 h-index	4991 167 g-index
267 all docs	267 docs citations	267 times ranked	31353 citing authors

#	Article	IF	Citations
1	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486, 395-399.	27.8	1,778
2	*ARID1A* Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	27.0	1,460
3	Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 2009, 461, 809-813.	27.8	984
4	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
5	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	10.7	753
6	Mutation of *FOXL2* in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	27.0	706
7	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Medicine, 2008, 5, e232.	8.4	675
8	Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer. Cancer, 2017, 123, 802-813.	4.1	552
9	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature, 2015, 518, 422-426.	27.8	545
10	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	7.1	540
11	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	3.2	495
12	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline *CDH1* mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
13	deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data. PLoS Computational Biology, 2011, 7, e1001138.	3.2	477
14	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	27.0	451
15	Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations. New England Journal of Medicine, 2001, 344, 1904-1909.	27.0	420
16	Recurrent Somatic *DICER1* Mutations in Nonepithelial Ovarian Cancers. New England Journal of Medicine, 2012, 366, 234-242.	27.0	401
17	Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2360.	7.4	394
18	EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer. Cell, 2003, 115, 523-535.	28.9	389

#	Article	IF	Citations
19	Distinct evolutionary trajectories of primary high‑grade serous ovarian cancers revealed through spatial mutational profiling. Journal of Pathology, 2013, 231, 21-34.	4.5	357
20	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
21	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	10.7	335
22	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. International Journal of Gynecological Pathology, 2010, 29, 203-211.	1.4	332
23	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Research, 2014, 24, 1881-1893.	5.5	322
24	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genetics, 2014, 46, 427-429.	21.4	298
25	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nature Genetics, 2016, 48, 758-767.	21.4	287
26	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
27	Use of mutation profiles to refine the classification of endometrial carcinomas. Journal of Pathology, 2012, 228, 20-30.	4.5	261
28	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	28.9	261
29	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
30	Model of the early development of diffuse gastric cancer in E‑cadherin mutation carriers and its implications for patient screening. Journal of Pathology, 2004, 203, 681-687.	4.5	242
31	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	7.1	239
32	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237
33	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. American Journal of Obstetrics and Gynecology, 2014, 210, 471.e1-471.e11.	1.3	236
34	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nature Reviews Cancer, 2017, 17, 65-74.	28.4	235
35	Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic Oncology, 2011, 121, 407-415.	1.4	225
36	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	21.4	220

#	Article	IF	Citations
37	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Modern Pathology, 2014, 27, 128-134.	5.5	218
38	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548.	7.0	217
39	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21.	3.7	211
40	Loss of BAF250a (<i>ARID1A</i>) is frequent in highâ€grade endometrial carcinomas. Journal of Pathology, 2011, 224, 328-333.	4.5	210
41	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. American Journal of Human Genetics, 2016, 98, 830-842.	6.2	201
42	Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE, 2013, 8, e72162.	2.5	200
43	SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics, 2010, 26, 730-736.	4.1	192
44	Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management. Clinical Cancer Research, 2005, 11, 5401-5409.	7.0	187
45	Germline CDH1 deletions in hereditary diffuse gastric cancer families. Human Molecular Genetics, 2009, 18, 1545-1555.	2.9	185
46	An Î±â€Eâ€catenin (<i><scp>CTNNA1</scp></i>) mutation in hereditary diffuse gastric cancer. Journal of Pathology, 2013, 229, 621-629.	4.5	184
47	FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. American Journal of Surgical Pathology, 2011, 35, 484-494.	3.7	183
48	The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas. International Journal of Gynecological Cancer, 2009, 19, 58-64.	2.5	181
49	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. International Journal of Gynecological Pathology, 2016, 35, 430-441.	1.4	180
50	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Research and Treatment, 2008, 107, 249-257.	2.5	179
51	Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. Journal of Clinical Oncology, 2006, 24, 5637-5644.	1.6	177
52	Gastric cancer: New genetic developments. Journal of Surgical Oncology, 2005, 90, 114-133.	1.7	176
53	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 2009, 9, 433.	2.6	175
54	ARID1A-mutated ovarian cancers depend on HDAC6Âactivity. Nature Cell Biology, 2017, 19, 962-973.	10.3	173

#	Article	IF	Citations
55	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <scp>HER2</scp> targeting in 19% of carcinomas. Journal of Pathology, 2013, 229, 111-120.	4.5	169
56	Dual loss of the <scp>SWI</scp>/<scp>SNF</scp> complex <scp>ATPases SMARCA4</scp>/<scp>BRG1</scp> and <scp>SMARCA2</scp>/<scp>BRM</scp> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2016, 238, 389-400.	4.5	169
57	Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Human Molecular Genetics, 2003, 12, 575-582.	2.9	167
58	CDH1 Truncating Mutations in the E-Cadherin Gene. Annals of Surgery, 2007, 245, 873-879.	4.2	157
59	Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Human Mutation, 2002, 19, 510-517.	2.5	153
60	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecologic Oncology, 2016, 143, 46-53.	1.4	153
61	A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nature Genetics, 2000, 26, 362-364.	21.4	152
62	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
63	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. American Journal of Surgical Pathology, 2010, 34, 984-993.	3.7	143
64	Quantification of Epigenetic and Genetic 2nd Hits in CDH1 During Hereditary Diffuse Gastric Cancer Syndrome Progression. Gastroenterology, 2009, 136, 2137-2148.	1.3	142
65	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget, 2015, 6, 37663-37677.	1.8	142
66	Endometrial Carcinomas with <i>POLE</i> Exonuclease Domain Mutations Have a Favorable Prognosis. Clinical Cancer Research, 2016, 22, 2865-2873.	7.0	139
67	The biological and clinical value of p53 expression in pelvic high‑grade serous carcinomas. Journal of Pathology, 2010, 222, 191-198.	4.5	136
68	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. Journal of Pathology, 2015, 236, 201-209.	4.5	131
69	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
70	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. Journal of the National Cancer Institute, 2015, 108, djv428.	6.3	128
71	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475.	5.5	125
72	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Modern Pathology, 2004, 17, 690-695.	5.5	123

#	Article	IF	Citations
73	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Modern Pathology, 2016, 29, 302-314.	5.5	123
74	Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer, 2008, 7, 73-82.	1.9	117
75	Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer, 2008, 47, 481-489.	2.8	116
76	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer, 2015, 15, 415.	2.6	116
77	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. American Journal of Surgical Pathology, 2013, 37, 1421-1432.	3.7	115
78	Subtype-specific mutation of *PPP2R1A* in endometrial and ovarian carcinomas. Journal of Pathology, 2011, 223, 567-573.	4.5	114
79	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	8.2	112
80	Loss of *ARID1A*-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers. International Journal of Gynecological Cancer, 2012, 22, 9-14.	2.5	108
81	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research, 2008, 10, R86.	5.0	107
82	Oncogenic mutations in histologically normal endometrium: the new normal?. Journal of Pathology, 2019, 249, 173-181.	4.5	106
83	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Modern Pathology, 2020, 33, 1595-1605.	5.5	103
84	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. Nature Communications, 2015, 6, 8554.	12.8	102
85	Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research. Scientific Reports, 2016, 6, 34949.	3.3	100
86	Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Human Pathology, 2003, 34, 1001-1008.	2.0	99
87	Calculator for ovarian carcinoma subtype prediction. Modern Pathology, 2011, 24, 512-521.	5.5	95
88	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Journal of Physical Education and Sports Management, 2015, 1, a000570.	1.2	92
89	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Research and Treatment, 2008, 110, 417-426.	2.5	91
90	Hereditary diffuse gastric cancer. Cancer, 2008, 112, 2655-2663.	4.1	89

#	Article	IF	Citations
91	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
92	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Modern Pathology, 2016, 29, 1586-1593.	5.5	87
93	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. British Journal of Cancer, 2018, 119, 480-486.	6.4	86
94	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecologic Oncology, 2016, 141, 454-460.	1.4	85
95	The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS ONE, 2009, 4, e7988.	2.5	82
96	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	2.5	82
97	Small-Cell Carcinoma of the Ovary, Hypercalcemic Typeâ€"Genetics, New Treatment Targets, and Current Management Guidelines. Clinical Cancer Research, 2020, 26, 3908-3917.	7.0	82
98	E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Human Molecular Genetics, 2003, 12, 3007-3016.	2.9	79
99	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecologic Oncology, 2006, 100, 264-270.	1.4	78
100	The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2017, 242, 371-383.	4.5	78
101	Class I HDAC inhibitors enhance YB â€'1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	4.5	78
102	Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology, 2015, 66, 664-674.	2.9	77
103	The role of the fallopian tube in ovarian cancer. Clinical Advances in Hematology and Oncology, 2012, 10, 296-306.	0.3	77
104	Rare cancers: a sea of opportunity. Lancet Oncology, The, 2016, 17, e52-e61.	10.7	76
105	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Modern Pathology, 2013, 26, 860-867.	5.5	74
106	Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology, 2020, 156, 715-725.	1.4	74
107	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686.	2.5	70
108	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. American Journal of Surgical Pathology, 2015, 39, 1548-1557.	3.7	70

#	Article	IF	Citations
109	Inâ€depth molecular profiling of the biphasic components of uterine carcinosarcomas. Journal of Pathology: Clinical Research, 2015, 1, 173-185.	3.0	70
110	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. Journal of Pathology: Clinical Research, 2017, 3, 279-293.	3.0	70
111	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
112	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. Journal of Pathology, 2017, 243, 26-36.	4.5	69
113	Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer, 2009, 9, 165.	2.6	68
114	Immunohistochemical characterization of prototypical endometrial clear cell carcinomaâ€"diagnostic utility of <scp>HNF</scp>â€‑1Î² and oestrogen receptor. Histopathology, 2014, 64, 585-596.	2.9	68
115	A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer, 2014, 14, 120.	2.6	68
116	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	2.6	67
117	De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Laboratory Investigation, 2010, 90, 1604-1614.	3.7	66
118	The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2013, 182, 1163-1170.	3.8	66
119	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 2018, 24, 2328-2341.	7.0	63
120	MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathology, 2006, 19, 69-74.	5.5	62
121	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecologic Oncology, 2019, 154, 516-523.	1.4	62
122	Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Annals of Medicine, 2017, 49, 435-447.	3.8	61
123	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Modern Pathology, 2011, 24, 64-81.	5.5	60
124	Familial rhabdoid tumour '<i>avant la lettre</i> '-from pathology review to exome sequencing and back again. Journal of Pathology, 2013, 231, 35-43.	4.5	60
125	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. Neoplasia, 2015, 17, 650-660.	5.3	59
126	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Modern Pathology, 2007, 20, 1156-1165.	5.5	58

#	Article	IF	Citations
127	Adult-Type Granulosa Cell Tumors and FOXL2 Mutation. Cancer Research, 2009, 69, 9160-9162.	0.9	58
128	Germline Mutations in MAP3K6 Are Associated with Familial Gastric Cancer. PLoS Genetics, 2014, 10, e1004669.	3.5	57
129	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
130	Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecologic Oncology, 2018, 151, 53-60.	1.4	54
131	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
132	Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. Journal of Pathology, 2021, 253, 41-54.	4.5	54
133	HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. Annals of Surgery, 2010, 251, 1107-1116.	4.2	53
134	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. Journal of Pathology, 2020, 252, 178-188.	4.5	53
135	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Medicine, 2007, 5, 33.	5.5	52
136	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology, 2016, 69, 727-738.	2.9	52
137	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. Journal of the National Cancer Institute, 2016, 108, djw134.	6.3	52
138	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. Molecular Cancer Research, 2017, 15, 250-258.	3.4	52
139	Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. Nature Communications, 2020, 11, 2020.	12.8	52
140	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Experimental Cell Research, 2005, 310, 99-104.	2.6	51
141	Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer. Breast Cancer Research, 2010, 12, R6.	5.0	51
142	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling, 2017, 10, .	3.6	51
143	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clinical Cancer Research, 2018, 24, 1932-1943.	7.0	51
144	The molecular pathology of cancer: from pan‐genomics to post‐genomics. Journal of Pathology, 2018, 244, 509-511.	4.5	50

#	Article	IF	Citations
145	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Molecular Cancer Therapeutics, 2018, 17, 2767-2779.	4.1	50
146	TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern Pathology, 2018, 31, 1107-1115.	5.5	49
147	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
148	SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 467-492.	22.4	47
149	The genomic landscape of epithelioid sarcoma cell lines and tumours. Journal of Pathology, 2016, 238, 63-73.	4.5	43
150	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
151	BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 825-832.	2.5	42
152	Clear cell carcinomas of the ovary and kidney: clarity through genomics. Journal of Pathology, 2018, 244, 550-564.	4.5	41
153	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Network Open, 2022, 5, e2147343.	5.9	41
154	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Diseases (Austin, Tex), 2014, 2, e967148.	1.8	40
155	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. Modern Pathology, 2021, 34, 508-518.	5.5	40
156	ARID1A regulates R-loop associated DNA replication stress. PLoS Genetics, 2021, 17, e1009238.	3.5	40
157	Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet Journal of Rare Diseases, 2013, 8, 33.	2.7	38
158	Recurrent *DICER1* hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. Journal of Pathology, 2015, 237, 215-225.	4.5	38
159	Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Research and Treatment, 2010, 121, 347-354.	2.5	37
160	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
161	A current perspective on the pathological assessment of *FOXL2* in adult‐type granulosa cell tumours of the ovary. Histopathology, 2014, 64, 380-388.	2.9	36
162	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer, 2021, 2, 189-200.	13.2	36

#	Article	IF	Citations
163	Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing. PLoS ONE, 2015, 10, e0119689.	2.5	36
164	Hereditary Diffuse Gastric Cancer: Prophylactic Surgical Oncology Implications. Surgical Clinics of North America, 2008, 88, 759-778.	1.5	35
165	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
166	Genomic Instability of Human Mammary Epithelial Cells Overexpressing a Truncated Form of EMSY. Journal of the National Cancer Institute, 2005, 97, 1302-1306.	6.3	34
167	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268.	2.0	34
168	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer, 2015, 15, 32.	2.6	34
169	Base excision repair deficiency signatures implicate germline and somatic *MUTYH* aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Journal of Physical Education and Sports Management, 2019, 5, a003681.	1.2	33
170	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. International Journal of Gynecological Cancer, 2015, 25, 1187-1193.	2.5	31
171	A structured latent model for ovarian carcinoma subtyping from histopathology slides. Medical Image Analysis, 2017, 39, 194-205.	11.6	31
172	Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Cancer Cell International, 2019, 19, 10.	4.1	31
173	Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. Journal of Pathology, 2020, 252, 201-214.	4.5	31
174	Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Research, 2008, 10, R6.	5.0	29
175	Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities. Journal of Pathology, 2011, 225, 12-18.	4.5	29
176	APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecologic Oncology, 2017, 147, 663-671.	1.4	29
177	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. Journal of Molecular Diagnostics, 2017, 19, 126-136.	2.8	29
178	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 97-104.	2.5	29
179	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma. International Journal of Gynecological Pathology, 2016, 35, 209-221.	1.4	28
180	DICER1 hot-spot mutations in ovarian gynandroblastoma. Histopathology, 2018, 73, 306-313.	2.9	28

#	Article	IF	Citations
181	Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. American Journal of Obstetrics and Gynecology, 2020, 223, 221.e1-221.e11.	1.3	28
182	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer, 2014, 14, 982.	2.6	27
183	Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. American Journal of Obstetrics and Gynecology, 2018, 219, 172.e1-172.e8.	1.3	27
184	Adult–type granulosa cell tumor of the ovary: a <scp><i>FOXL2</i></scp>–centric disease. Journal of Pathology: Clinical Research, 2021, 7, 243-252.	3.0	27
185	Pregnancy after prophylactic total gastrectomy. Familial Cancer, 2010, 9, 331-334.	1.9	26
186	Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	4.1	26
187	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
188	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
189	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
190	Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1039-1046.	5.2	21
191	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Clinical Cancer Research, 2020, 26, 4402-4413.	7.0	21
192	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	5.5	21
193	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic Oncology, 2021, 160, 568-578.	1.4	21
194	Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor. Oncologist, 2014, 19, 623-630.	3.7	20
195	Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Scientific Reports, 2017, 7, 10574.	3.3	20
196	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. Gynecologic Oncology, 2022, 165, 376-384.	1.4	20
197	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. BMC Cancer, 2018, 18, 254.	2.6	19
198	The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity. Cancer Research, 2020, 80, 3480-3491.	0.9	19

#	ARTICLE	IF	CITATIONS
199	The utility of color normalization for <scp>AI</scp>â€based diagnosis of hematoxylin and eosinâ€stained pathology images. Journal of Pathology, 2022, 256, 15-24.	4.5	19
200	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. ELife, 2020, 9, .	6.0	19
201	A New Method for Characterization and Epitope Determination of a Lupus Anticoagulantâ€"Associated Neutralizing Antiprothrombin Antibody. American Journal of Clinical Pathology, 1997, 107, 197-205.	0.7	18
202	Boveri at 100: Theodor Boveri and genetic predisposition to cancer. Journal of Pathology, 2014, 234, 142-145.	4.5	18
203	Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. Gynecologic Oncology, 2022, 165, 201-214.	1.4	18
204	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. Modern Pathology, 2020, 33, 1649-1659.	5.5	17
205	Hereditary Diffuse Gastric Cancer. Cancer Treatment and Research, 2010, 155, 33-63.	0.5	17
206	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. PLoS ONE, 2016, 11, e0153844.	2.5	17
207	Using Somatic Mutations to Guide Treatment Decisions. JAMA Oncology, 2015, 1, 275.	7.1	15
208	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	1.4	15
209	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
210	Periodic Acid-Schiff Is Superior to Hematoxylin and Eosin for Screening Prophylactic Gastrectomies From CDH1 Mutation Carriers. American Journal of Surgical Pathology, 2010, 34, 1007-1013.	3.7	14
211	It Sounded Like a Good Idea at the Time. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1127-1130.	0.7	14
212	Distinct developmental trajectories of endometriotic epithelium and stroma: implications for the origins of endometriosis. Journal of Pathology, 2018, 246, 257-260.	4.5	14
213	Use of Immunohistochemical Markers (HNF-1Î², Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. International Journal of Gynecological Pathology, 2020, 39, 344-353.	1.4	14
214	Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. American Journal of Cancer Research, 2016, 6, 2235-2251.	1.4	14
215	LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. Gynecologic Oncology, 2017, 147, 642-647.	1.4	13
216	A comprehensive geneâ€"environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	5.1	12

#	Article	IF	Citations
217	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	2.7	12
218	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
219	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 132-141.	2.5	12
220	Mechanisms of monozygotic (MZ) twinning: A possible role for the cell adhesion molecule, E-cadherin. American Journal of Medical Genetics Part A, 2003, 120A, 59-62.	2.4	11
221	Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264.	4.5	11
222	Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of <i>In Vivo</i> Fallopian Tube Electroporation and CRISPR-Cas9â€"Mediated Genome Editing. Cancer Research, 2021, 81, 5147-5160.	0.9	11
223	Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation. PLoS ONE, 2017, 12, e0178989.	2.5	11
224	Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization. Journal of Pathology and Translational Medicine, 2020, 54, 480-488.	1.1	11
225	From biobank and data silos into a data commons: convergence to support translational medicine. Journal of Translational Medicine, 2021, 19, 493.	4.4	11
226	FOXL2 in adultâ€type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?. Journal of Pathology, 2021, 255, 225-231.	4.5	10
227	Loss of Sprouty2 in human highâ€grade serous ovarian carcinomas promotes EGFâ€induced Eâ€cadherin downâ€regulation and cell invasion. FEBS Letters, 2015, 589, 302-309.	2.8	9
228	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. Human Pathology, 2019, 92, 39-47.	2.0	9
229	Cancer genomics: why rare is valuable. Journal of Molecular Medicine, 2015, 93, 369-381.	3.9	8
230	The coming 15 Âyears in gynaecological pathology: digitisation, artificial intelligence, and new technologies. Histopathology, 2020, 76, 171-177.	2.9	8
231	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. Human Pathology, 2021, 108, 1-11.	2.0	8
232	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	1.8	7
233	Clinically-inspired automatic classification of ovarian carcinoma subtypes. Journal of Pathology Informatics, 2016, 7, 28.	1.7	7
234	Changing Clinical Practice. International Journal of Gynecological Cancer, 2018, 28, 1101-1107.	2.5	6

#	Article	IF	Citations
235	<scp>STING</scp> pathway expression in lowâ€grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. Journal of Pathology: Clinical Research, 2021, 7, 548-555.	3.0	6
236	Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status. Modern Pathology, 2022, 35, 77-81.	5.5	6
237	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 855-862.	2.8	5
238	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
239	Categorization of cancer through genomic complexity could guide research and management strategies. Journal of Pathology, 2015, 236, 397-402.	4.5	4
240	Proteomic analysis of transitional cell carcinomaâ€"like variant of tubo-ovarian high-grade serous carcinoma. Human Pathology, 2020, 101, 40-52.	2.0	4
241	Reply to â€œAn alternative miRISC targets a cancerâ€associated coding sequence mutation in FOXL2â€. EMBO Journal, 2021, 40, e107517.	7.8	3
242	The impact of whole genome and transcriptome analysis (<scp>WGTA</scp>) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies. Journal of Pathology: Clinical Research, 2022, 8, 395-407.	3.0	3
243	Podocalyxin : A Marker of Blasts in Acute Leukemia. American Journal of Clinical Pathology, 2005, 124, 134-142.	0.7	2
244	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€" a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	1.3	2
245	Reply to Perner and Rubin. Modern Pathology, 2008, 21, 1056-1057.	5.5	1
246	Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics, 2011, 4, 275-296.	1.7	1
247	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. PLoS ONE, 2020, 15, e0240412.	2.5	1
248	High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. American Journal of Pathology, 2018, 188, 1510-1516.	3.8	0
249	Beyond CDH1 Mutations: Causes of Hereditary Diffuse Gastric Cancer. , 2013, , 97-110.		0
250	Title is missing!. , 2020, 15, e0240412.		0
251	Title is missing!. , 2020, 15, e0240412.		0
252	Title is missing!. , 2020, 15, e0240412.		0

#	Article	IF	Citations
253	Title is missing!. , 2020, 15, e0240412.		0